A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.

NCT02717858 · Completed

Last updated 2026-05-28

This trial tests whether the medication liraglutide affects how the gallbladder empties in adults who are overweight or obese.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 52 people

Who can join all sexes

Timeline Started 2016-03 · est. completion 2017-02

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02717858 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.

Treatments tested

liraglutide Drug

Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
placebo Drug

Injected s.c./subcutaneously (under the skin) once daily.

Main thing measured	Maximum postprandial gallbladder ejection fraction (GBEFmax)
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02717858 ↗